A phase III study of Cannabidiol in prevention of acute graft versus host disease (GVHD)
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Sponsors Kalytera Therapeutics
- 11 Sep 2019 According to an Kalytera Therapeutics media release, the company announced that it is updating the terms of its private placement previously announced on August 21, 2019. The Company proposes to raise up to approximately CDN $1.5 million (USD $1.14 million) pursuant to the Private Placement.
- 21 Aug 2019 According to a Kalytera Therapeutics media release, the company intends to raise up to approximately CDN $1.5 million (USD $1.13 million) in a private placement. The proceeds will be utilized to fund preparatory work for initiation of phase 3 study in prevention of acute graft versus host disease.
- 05 Oct 2018 New trial record